BeOne Medicines (BEIGF) EBIT (2015 - 2026)

BeOne Medicines (BEIGF) has reported EBIT for 12 consecutive years, with $325.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 269.85% year-over-year to $325.0 million in Q2 2026; TTM through Jun 2026 was $923.1 million, a 1016.65% increase from a year earlier, with the FY2025 full-year figure at $447.1 million, up 178.69% from the prior year.
• EBIT was $325.0 million for Q2 2026 at BeOne Medicines, up from $249.9 million in the prior quarter.
• Over five years, EBIT peaked at $325.0 million in Q2 2026 and troughed at -$468.6 million in Q4 2022.
• A 5-year average of -$141.3 million and a median of -$127.1 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT plunged 731.76% in 2022 and surged 2150.96% in 2026, its largest moves.
• Over 5 years, EBIT stood at -$468.6 million in 2022, then rose by 18.1% to -$383.8 million in 2023, then surged by 79.31% to -$79.4 million in 2024, then surged by 332.97% to $185.0 million in 2025, then surged by 75.67% to $325.0 million in 2026.
• The last three EBIT figures came in at $325.0 million (Q2 2026), $249.9 million (Q1 2026), and $185.0 million (Q4 2025), per Business Quant data.